Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo
    February 17, 2017February 17, 2017

    RA Patients Treated with Olumiant Show Improvements Compared to Humira, Placebo

    News, rheumatoid arthritis
    In a pivotal Phase 3 clinical trial, Olumiant (baricitinib) improved patients’ outcomes in the treatment of moderate-to-severe rheumatoid arthritis (RA), in comparison to Humira (adalimumab) and placebo, according to a ... Read more
    European Commission OKs Marketing Olumiant Tablets for Adults with Active RA
    February 15, 2017February 15, 2017

    European Commission OKs Marketing Olumiant Tablets for Adults with Active RA

    News, rheumatoid arthritis
    The European Commission has granted marketing authorization for Olumiant (baricitinib) 4 mg and 2 mg tablets for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have ... Read more
    Newly Identified Genes May Contribute to Arthritis Risk in Arabs, Study Shows
    February 13, 2017February 13, 2017

    Newly Identified Genes May Contribute to Arthritis Risk in Arabs, Study Shows

    News
    A large genetic study confirmed that Arabs share a rheumatoid arthritis risk gene with other populations, but identified new genes that may be involved in triggering the disease in Arabs ... Read more
    Logan Levkoff Partners with Pfizer to Talk About Sex and Relationships for RA, Chronic Disease Patients
    February 10, 2017February 10, 2017

    Logan Levkoff Partners with Pfizer to Talk About Sex and Relationships for RA, Chronic Disease Patients

    News
    Relationship expert and author Logan Levkoff, PhD, is partnering with Pfizer to address intimacy and relationship issues for people living with rheumatoid arthritis (RA) and other chronic diseases. Levkoff , ... Read more
    Sanofi’s Kevzara Approved in Canada as Treatment for Moderate to Severe RA
    February 8, 2017February 8, 2017

    Sanofi’s Kevzara Approved in Canada as Treatment for Moderate to Severe RA

    News
    Kevzara (sarilumab) has been approved in Canada as a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) who are either intolerant or considered inappropriate candidates to be treated ... Read more
    Newly Identified T-cell in RA Patients May Leapfrog Autoimmune Treatment Development
    February 6, 2017February 6, 2017

    Newly Identified T-cell in RA Patients May Leapfrog Autoimmune Treatment Development

    News, rheumatoid arthritis
    An entirely new type of T-cell found in people with rheumatoid arthritis works in a unique way to drive disease processes in the joints by teaming up with other immune ... Read more
    CHMP Favors Xeljanz Be Approved to Treat Patients with Active Rheumatoid Arthritis in EU
    February 3, 2017February 3, 2017

    CHMP Favors Xeljanz Be Approved to Treat Patients with Active Rheumatoid Arthritis in EU

    News
    The  Committee for Medicinal Products for Human Use (CHMP) is recommending the approval of Pfizer’s Xeljanz (tofacitinib citrate, 5 mg tablets twice daily) as a treatment for adults with moderate-to-severely active rheumatoid arthritis (RA) in ... Read more
    EU Closer to Approving ABP 501 as Alternative to Humira for Rheumatoid Arthritis
    February 1, 2017February 1, 2017

    EU Closer to Approving ABP 501 as Alternative to Humira for Rheumatoid Arthritis

    News, rheumatoid arthritis
    Amgen has taken a key step toward obtaining European Union approval of its ABP 501 biosimilar therapy for rheumatoid arthritis (RA) and other conditions. The European Medicines Agency’s Committee for Medicinal Products for Human ... Read more
    NIH Awards $1.8M to Study of Enzyme’s Role in Potential Therapies for RA and Other Diseases
    January 30, 2017January 30, 2017

    NIH Awards $1.8M to Study of Enzyme’s Role in Potential Therapies for RA and Other Diseases

    News, rheumatoid arthritis
    A nearly $1.8 million grant given a research team at The Scripps Research Institute (TSRI) in Florida will be used to study an enzyme that controls cell survival and death, with the goal ... Read more
    Real-time Imaging Used to Identify Protein That Triggers Inflammatory Arthritis
    January 27, 2017January 27, 2017

    Real-time Imaging Used to Identify Protein That Triggers Inflammatory Arthritis

    News
    Using a novel imaging technique, researchers followed in real time the movement of immune cells in a live mouse and identified a key factor responsible for triggering inflammatory arthritis. The ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.